10-Q · April 29, 2026
Regeneron's Q1 2026 results revealed revenues of $3.605 billion, a significant increase from $3.029 billion in Q1 2025, but diluted EPS of $6.75 fell short of the consensus estimate of $8.38 primarily due to an R&D…
Earnings analysis · 10-Q
REGN earnings analysis
Filed October 30, 2026 · Our reading of the company's report
The latest report
Regeneron delivered a very strong Q3, with revenue up 36.3% to $5,115.8 million, diluted EPS up 35.5% to $18.45, and operating margin expanding to 40.0% from approximately 27.4% a year earlier. Growth was led by the…
Read full summary
Regeneron delivered a very strong Q3, with revenue up 36.3% to $5,115.8 million, diluted EPS up 35.5% to $18.45, and operating margin expanding to 40.0% from approximately 27.4% a year earlier. Growth was led by the Sanofi collaboration, Dupixent, EYLEA HD, and Libtayo, more than offsetting a 41% decline in U.S. EYLEA sales. Liquidity remains strong with $3,659.1 million of cash and $3,675.3 million of nine-month operating cash flow, but biosimilar pressure, government pricing commitments, patent challenges, and rising R&D investment remain material risks.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
Reported figures
- Earnings per share
- $18.45
- Operating margin
- 40.0%
What stood out
-
Revenue and EPS accelerated
Q3 revenue was $5,115.8 million, up $1,361.5 million, or 36.3%, from $3,754.3 million in Q3 2025. Net income increased to $1,948.7 million from $1,460.0 million, while diluted EPS rose to $18.45 from $13.62.
-
Operating leverage improved
Income from operations increased 99.5% year over year to $2,048.2 million from $1,026.8 million, implying a 40.0% operating margin versus approximately 27.4% in the prior-year quarter.
-
Sanofi collaboration surged
Sanofi collaboration revenue increased to $2,724.0 million from $1,617.0 million, while Regeneron's share of collaboration profits increased to $2,574.9 million from $1,455.5 million. Dupixent and Kevzara global sales reached $6,796.1 million, up from $5,011.0 million.
-
Core products grew strongly
Product momentum was broad outside legacy EYLEA: global Dupixent sales rose 35% to $6,540.5 million, EYLEA HD rose 63% to $1,082.8 million, Libtayo rose 51% to $550.0 million, and Kevzara rose 66% to $255.6 million.
-
Liquidity remained substantial
Cash and cash equivalents increased by $541.0 million to $3,659.1 million at September 30, 2026. Working capital increased by $939.5 million to $14,593.0 million, and the company retained $750.0 million of revolving-credit availability.
-
Strong cash generation funds investment
Operating cash flow was $3,675.3 million for the first nine months of 2026, despite being $132.9 million below the prior-year period. Management expects full-year capital expenditures of $1.050 billion to $1.100 billion, primarily for Tarrytown and manufacturing expansion.
What to watch
-
EYLEA faces accelerating competition
U.S. EYLEA net product sales declined 41% year over year in both the quarter and nine-month period, and global EYLEA sales fell 49% to $658.4 million. Management expects biosimilar competition and patient conversion to EYLEA HD to continue pressuring EYLEA sales.
-
Government pricing pressure increased
The April 2026 U.S. Government Agreements require certain wholly owned U.S. products to be supplied to Medicaid at Most-Favored-Nation prices and future medicines to be priced no higher than those prices. The agreements may reduce prices and reimbursement, although they provide tariff protection through January 2029 subject to investment commitments.
-
Pipeline investment is escalating
Research and development expense increased $319.7 million year over year to $1,794.7 million in Q3, while nine-month R&D expense rose $745.7 million to $4,969.8 million. Clinical manufacturing costs increased $126.3 million to $507.7 million, raising investment and execution risk across the pipeline.
-
EYLEA HD patent protection challenged
The March 2026 USPTO post-grant review of U.S. Patent No. 12,168,036 relating to EYLEA HD adds intellectual-property risk, while EYLEA biosimilars have already launched after U.S. exclusivity ended in May 2024.
-
AI governance risk emerging
The filing newly highlights AI-related operational and compliance risks, including potentially inaccurate or biased outputs, unauthorized disclosure of sensitive data, and unauthorized actions by agentic systems. Regeneron states that such events could materially affect the business, prospects, operating results, and financial condition.
-
Manufacturing disruption pressured margin
Gross margin on net product sales was 79% for the first nine months of 2026 versus 82% in the prior-year period, primarily due to unabsorbed manufacturing costs from a temporary Limerick interruption. The interruption began in Q1 2026 and production returned to normal by June 30, 2026.
Management's outlook
No numeric revenue or EPS guidance was provided. Management expects full-year 2026 capital expenditures of $1.050 billion to $1.100 billion. The October 2026 Sanofi amendment is expected to contribute a $1.0 billion upfront payment to Collaboration revenue in Q4 2026; up to an additional $7.0 billion is contingent on development, regulatory, and sales milestones.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.